<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### [Newly added reference (Sep 29)](/page/updates/#newly.added.reference.sep.29.)

Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=Brunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).

### [Newly added reference (Sep 29)](/page/updates/#newly.added.reference.sep.29.)

Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Curreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).

### [New clinical trials (Sep 28)](/page/updates/#new.clinical.trials.sep.28.)

14 clinical trials were added since September 24: [list of new clinical trials](/clinical-trials/?fromDate=2020-09-24).

### [Published preprints (Sep 28)](/page/updates/#published.preprints.sep.16.sep.28.)

3 published preprints were added since September 16.

### [Newly added reference (Sep 25)](/page/updates/#newly.added.reference.sep.25.)

ter Ellen BM, Dinesh Kumar N, et int., and Smit JM. [‚ÄúResveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.‚Äù](/search/?article=Ellen%20ter20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).

### [New spike structure (Sep 24)](/page/updates/#new.spike.structure.sep.24.)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#new.table.added.sep.24.)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### [Newly added reference (Sep 23)](/page/updates/#newly.added.reference.sep.23.)

Cao L, Goreshnik I, et int., and Baker D. [‚ÄúDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors.‚Äù](/search/?article=Cao20e) _Science_, 2020. [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909). [PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)

### [Interface update (Sep 22)](/page/updates/#interface.update.sep.22.)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#a.sars-cov-2.antiviral.therapy.score.card.sep.21.)

Shafer R. ‚ÄúA SARS-CoV-2 antiviral therapy score card‚Äù _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

